Overview

Adbelizumab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer

Status:
Recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
Clinical Study on the Safety and Efficacy of the efficacy and safety of adbelizumab combined with chemotherapy for neoadjuvant treatment of resectable pancreatic cancer
Phase:
Phase 2
Details
Lead Sponsor:
Jinling Hospital, China
Collaborator:
Jiangsu Hengrui Pharmaceutical Co., Ltd.
Treatments:
Albumin-Bound Paclitaxel
Gemcitabine
Paclitaxel